Survodutide
Dual GLP-1/glucagon receptor agonist; investigational once-weekly injectable for obesity and MASH (Boehringer Ingelheim).
Quick Facts
| Property | Value |
|---|---|
| Also Known As | BI 456906 |
| Category | Dual GLP-1/Glucagon Receptor Agonist (Metabolic) |
| Sequence | Modified peptide with GLP-1 and glucagon receptor agonist activities (proprietary; acylated for albumin binding and extended half-life) |
| Molecular Weight | ~4000 Da (estimated) |
| Molecular Formula | Not publicly disclosed |
| PubChem CID | N/A (investigational) |
| Administration | SubQ once weekly |
| Typical Dose Range | 0.6-6.0 mg once weekly (dose-escalation over 16-20 weeks) |
| Half-Life | ~6 days |
| Storage | Refrigerate 2-8C (investigational supply) |
| FDA Status | Investigational — Phase 3 (SYNCHRONIZE program for obesity); Phase 2b completed for MASH |
| WADA Status | Not listed (investigational) |
Mechanism of Action
Survodutide is a rationally designed peptide that simultaneously activates two receptors: the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR). This dual agonism produces metabolic effects that exceed those achievable by GLP-1R agonism alone, by engaging fundamentally different metabolic pathways through each receptor.
GLP-1R agonism provides the established incretin effects: glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and central appetite suppression through hypothalamic GLP-1R activation. These are the same mechanisms exploited by semaglutide, liraglutide, and other GLP-1 RAs.
Glucagon receptor agonism adds a mechanistically distinct metabolic dimension:
- Hepatic lipid oxidation — Glucagon activates hepatic AMPK and PPARalpha signaling, promoting beta-oxidation of fatty acids. This directly addresses hepatic steatosis and is the key mechanism for MASH/NAFLD benefit.
- Increased energy expenditure — Glucagon increases resting energy expenditure through thermogenesis, particularly in brown adipose tissue and through futile cycling pathways. This adds caloric expenditure on top of the caloric reduction from GLP-1-mediated appetite suppression.
- Amino acid metabolism — Glucagon stimulates hepatic amino acid catabolism and ureagenesis, contributing to the overall increase in energy expenditure.
The critical design challenge was balancing the opposing glycemic effects: GLP-1R agonism lowers glucose while GCGR agonism raises it (glucagon is the counter-regulatory hormone). Survodutide was selected from 19 candidate molecules based on its optimal GLP-1R:GCGR activity ratio, achieving robust weight loss and hepatic fat reduction without clinically significant hyperglycemia (PMID: 38560764 — biomarker/pharmacological profiling paper).
Survodutide is differentiated from Tirzepatide (GIP/GLP-1 dual agonist) and Retatrutide (GIP/GLP-1/glucagon triple agonist). The glucagon receptor engagement is what distinguishes survodutide from tirzepatide, while the absence of GIP agonism distinguishes it from retatrutide. Mazdutide (IBI362, Innovent/Lilly) shares the same dual GLP-1/GCGR agonist mechanism and was approved in China in 2024 for chronic weight management.
Key Research Areas
- Obesity Treatment — Phase 2 trial demonstrated up to 14.9% body weight loss at 46 weeks with the 4.8 mg dose (PMID: 38330987)
- MASH/NAFLD — Phase 2 NEJM trial showed 62% MASH resolution rate at 4.8 mg vs. 14% placebo (PMID: 38847460)
- Type 2 Diabetes — Phase 2 trial showed HbA1c reductions up to -1.71% with weight loss up to -8.7%, superior to open-label semaglutide 1.0 mg for weight loss (PMID: 38095657)
- Cardiovascular Effects — Post-hoc analysis showed significant blood pressure improvements; SYNCHRONIZE-CV outcomes trial is planned
- Hepatic Lipid Metabolism — Glucagon-mediated hepatic fat oxidation provides a mechanistic advantage for liver disease applications
Evidence Level Summary
| Evidence Type | Count | Notes |
|---|---|---|
| Human RCTs | 3 | Phase 2 (obesity, MASH, T2D) |
| Human observational | 0 | Investigational — no real-world data yet |
| Animal in vivo | 5+ | Preclinical dual-agonist pharmacology |
| In vitro | 3+ | Receptor binding, signaling characterization |
| Systematic reviews | 1 | Meta-analysis of weight loss data |
Clinical Applications
- Weight Management — Investigational; Phase 3 SYNCHRONIZE program ongoing for obesity
- NAFLD — Investigational; Phase 2 showed strong MASH resolution; glucagon component mechanistically targeted
- Type 2 Diabetes — Investigational; dual glycemic control + weight loss
- Metabolic Syndrome — Broad cardiometabolic improvements observed across Phase 2 trials
Protocols Using This Peptide
No current vault protocols include survodutide as it remains investigational. It may be incorporated into the Weight Loss Protocol and Metabolic Reset Protocol if FDA-approved.
Ageless Peps Products
- APWS-Survodutide-Vial — Survodutide 10mg Vial, $65, wholesale only (clinical label, investigational compound)
Dosing Reference
Clinical Trial Dosing (Investigational)
| Route | Dose Range | Frequency | Duration | Source |
|---|---|---|---|---|
| SubQ (Obesity) | 0.6 mg -> 4.8 mg (escalation) | Once weekly | 46 weeks (Phase 2) | PMID 38330987 |
| SubQ (MASH) | 2.4 mg, 4.8 mg, 6.0 mg | Once weekly | 48 weeks (Phase 2) | PMID 38847460 |
| SubQ (T2D) | 0.3 mg -> 4.8 mg (escalation) | Once weekly | 16 weeks (Phase 2) | PMID 38095657 |
Dose Escalation
Dose escalation occurs over 16-20 weeks depending on the target dose and indication, primarily to manage GI tolerability. The 4.8 mg dose appears to offer the best benefit-risk profile across indications; the 6.0 mg dose did not show additional efficacy in MASH and had higher discontinuation rates.
Cycling
Not applicable (chronic therapy in clinical trials).
Contraindications & Safety
- Contraindications (observed in trials): Personal/family history of MTC, MEN2 (precautionary, consistent with GLP-1 RA class)
- Common side effects: Nausea (44-66%), diarrhea (19-30%), vomiting (20-30%), decreased appetite, constipation — rates are higher than pure GLP-1 RAs, likely reflecting the glucagon component
- Drug interactions: Expected GI slowing effects on oral medication absorption (class effect)
- Pregnancy/nursing: Not studied; expected contraindication
- Special populations: Limited data; hepatic impairment studied in cirrhosis (PMID: 38857788 — survodutide PK in cirrhosis)
- Unique safety consideration: Theoretical hyperglycemia risk from glucagon agonism, though not clinically observed at therapeutic doses due to GLP-1R counterbalance
Synergistic Combinations
As an investigational dual agonist, survodutide is designed to be a monotherapy combining two mechanisms in a single molecule. Combination approaches have not been studied.
Competitive Landscape
| Agent | Mechanism | Key Differentiator |
|---|---|---|
| Semaglutide | GLP-1 only | Established safety/efficacy; approved for obesity and T2D |
| Tirzepatide | GIP/GLP-1 | Greater weight loss (~20%+); different dual mechanism |
| Retatrutide | GIP/GLP-1/Glucagon | Triple agonist; includes both GIP and glucagon |
| Survodutide | GLP-1/Glucagon | Unique glucagon-driven hepatic fat oxidation; strongest MASH data |
Related Research
| PMID | Title | Year | Study Type |
|---|---|---|---|
| 38330987 | Survodutide for obesity: Phase 2 dose-finding trial | 2024 | RCT |
| 38847460 | Phase 2 trial of survodutide in MASH and fibrosis | 2024 | RCT |
| 38095657 | Survodutide dose-response in type 2 diabetes vs. placebo and semaglutide | 2024 | RCT |
References
- PMID 38330987 — Phase 2 obesity dose-finding trial
- PMID 38847460 — Phase 2 MASH and fibrosis trial (NEJM)
- PMID 38095657 — Phase 2 T2D dose-response trial
Related
#peptide #metabolic #investigational #not-sold #subq